3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
6
Neuroblastoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Fallopian Tube Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Congenital Abnormalities
1
Interventions
Temozolomide
162
Radiosurgery
115
Radiotherapy
100
Bevacizumab
96
Magnetic Resonance Spectroscopy
65
Carboplatin
48
Etoposide
34
pembrolizumab
33
Surgical Procedures, Operative
33
Irinotecan
33
Nivolumab
32
Cyclophosphamide
32
Erlotinib Hydrochloride
31
Radiation
30
Carmustine
28
Lomustine
25
Cisplatin
25
Trastuzumab
23
Ipilimumab
23
Filgrastim
23
Vincristine
20
Mental Status and Dementia Tests
20
Aminolevulinic Acid
19
Topotecan
18
Pemetrexed
18
Capecitabine
18
Specimen Handling
17
Sorafenib
15
Radiotherapy, Intensity-Modulated
15
Imatinib Mesylate
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Brain Neoplasms
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts